Adherence to a “Southern diet” may be the biggest driver of racial disparities in hypertension rates among black and white adults in the U.S., according to a prospective cohort study published Oct. 2 in JAMA.

Women who suffer from peripartum cardiomyopathy (PPCM) will likely be clinically asymptomatic seven years after they give birth, according to research published in the Journal of the American Heart Association Oct. 3—but it’s also likely they’ll develop enduring diastolic dysfunction and reduced exercise capacity in the same window.

The consequences of sexual harassment and assault—the former of which up to 81 percent of women say they’ve experienced at some point in their lifetime—aren’t just mental, according to a study presented at the North American Menopause Society symposium in San Diego. They’re also physical, putting women at a higher risk for hypertension and sleep disorders.

Metabolic parameters like body weight, blood pressure, cholesterol and blood sugar levels are established risk factors for cardiovascular disease. But a new study suggests it’s not just abnormal measures of these components that portend risk—significant fluctuations in these areas are independently linked to all-cause mortality, heart attack and stroke among otherwise healthy people.

SAN DIEGO — An endovascular ultrasound-based renal denervation (RDN) approach led to greater reductions in blood pressure than radiofrequency ablation in patients with resistant hypertension, according to the first randomized trial to compare the techniques.

A recent meta-analysis published in Circulation: Cardiovascular Quality and Outcomes suggests the benefit of anticoagulation for pulmonary arterial hypertension (PAH) may depend on the subtype of the condition. Mortality rates improved with anticoagulation for patients with idiopathic PAH but worsened for those with scleroderma-associated PAH.

About 14 percent of older adults hospitalized for common, non-cardiac conditions were discharged with more intensive blood pressure medication, according to an analysis published in The BMJ. The concerning part: More than half of those patients actually demonstrated good blood pressure (BP) control in an outpatient setting, suggesting overtreatment from hospital physicians.

The European Medicines Agency (EMA) and the FDA said late last week a second toxin that may cause cancer has been detected in valsartan—a common heart drug that has already been recalled in about two dozen countries due to the presence of N-nitrosodimethylamine (NDMA), a probable human carcinogen.

The American Heart Association has tightened its guidelines for diagnosing resistant hypertension—a condition that affects up to 15 percent of patients treated for high blood pressure—according to a scientific statement published this month.

Scientists have developed a wearable ultrasound device to measure central blood pressure (BP). It performed as well as a current noninvasive technique upon testing, according to a press release.

Carcinogen-containing valsartan products that were recalled in about two dozen countries over the past few months didn’t significantly raise cancer risk in the short term, according to a Danish registry study published online Sept. 12 in The BMJ.

The concept of “time in range” has been used in warfarin monitoring and glycemic management for diabetic patients, but why hasn't it caught on as a useful metric in controlling hypertension?